argenex SE (NASDAQ:ARGX) Receives $1,017.78 Average PT from Analysts

Shares of argenex SE (NASDAQ:ARGX) have been given an average recommendation of “Moderate Buy” by the twenty-four ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $1,019.50.

Several brokerages have recently issued reports on ARGX. Wells Fargo & Company upped their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a report on Monday, June 1st. HC Wainwright upped their target price on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Royal Bank Of Canada lowered their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Oppenheimer lowered their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Finally, Glj Research upgraded shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in shares of argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares in the last quarter. Capital World Investors raised its position in argenex by 0.4% in the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares during the last quarter. M&T Bank Corp raised its position in argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Wellington Management Group LLP raised its position in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the last quarter. Finally, Morgan Stanley raised its position in argenex by 19.2% in the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after purchasing an additional 83,746 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Trading Up 5.8%

Shares of NASDAQ:ARGX opened at $891.32 on Monday. argenex has a 52 week low of $510.05 and a 52 week high of $934.62. The company’s 50 day moving average is $794.90 and its two-hundred day moving average is $813.42. The company has a market cap of $55.43 billion, a PE ratio of 39.68, a P/E/G ratio of 1.29 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The business had revenue of $1.31 billion during the quarter. As a group, equities research analysts expect that argenex will post 26.19 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.